Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatiti
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
07:30am, Tuesday, 29'th Apr 2025
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corpor
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
04:00pm, Tuesday, 22'nd Apr 2025
EMERYVILLE, Calif. , April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
04:05pm, Monday, 21'st Apr 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DV
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
07:15am, Thursday, 17'th Apr 2025
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board
Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer
08:00am, Wednesday, 16'th Apr 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:
Dynavax Files Preliminary Proxy Statement
05:40pm, Thursday, 03'rd Apr 2025
Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
11:45am, Thursday, 20'th Mar 2025
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
06:00am, Thursday, 06'th Mar 2025
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, inc
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
05:58pm, Monday, 03'rd Mar 2025
Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its sup
Dynavax to Participate in Upcoming Investor Conferences
04:10pm, Tuesday, 25'th Feb 2025
EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, t
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet
10:55am, Monday, 24'th Feb 2025
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
06:38pm, Thursday, 20'th Feb 2025
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communicati
Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates
06:10pm, Thursday, 20'th Feb 2025
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago.
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
04:01pm, Thursday, 20'th Feb 2025
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in
